Literature DB >> 23016685

Matriptase-2, a regulatory protease of iron homeostasis: possible substrates, cleavage sites and inhibitors.

Marit Stirnberg1, Michael Gütschow.   

Abstract

Matriptase-2 is a cell surface serine protease with a modular structure. The exploration of its function in iron homeostasis was of significance for the understanding of the regulation of hepcidin expression, the master protein in iron control. Mutations in matriptase- 2 cause iron-refractory iron deficiency anemia (IRIDA), an iron deficiency disorder where the level of hepcidin is inappropriately high. Matriptase-2 controls hepcidin expression through the suppression of bone morphogenetic protein (BMP)/sons of mothers against decapentaplegic homologue protein (SMAD) signaling, probably by cleaving the BMP co-receptor hemojuvelin. Since prospective studies revealed that genetic inactivation of matriptase-2 reduces iron loading in different mouse models, matriptase-2 becomes highly attractive as a novel target for the design of low-molecular weight inhibitors. The first synthetic peptidomimetic matriptase-2 inhibitors have been reported. A computational model of the active site of matriptase-2 based on the X-ray crystal structure of the close homologue matriptase was generated and mutational studies were performed in order to identify critical amino acids specifying the preferred recognition site of matriptase-2. So far, the only known putative natural substrates of matriptase-2 are hemojuvelin and matriptase-2 itself, as this protease undergoes complex auto-processing during zymogen activation. Cleavage sites within both natural substrates were identified.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23016685     DOI: 10.2174/1381612811319060007

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  7 in total

1.  Deletion of hemojuvelin, an iron-regulatory protein, in mice results in abnormal angiogenesis and vasculogenesis in retina along with reactive gliosis.

Authors:  Amany Tawfik; Jaya P Gnana-Prakasam; Sylvia B Smith; Vadivel Ganapathy
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-08       Impact factor: 4.799

Review 2.  Physiology of iron metabolism.

Authors:  Sophie Waldvogel-Abramowski; Gérard Waeber; Christoph Gassner; Andreas Buser; Beat M Frey; Bernard Favrat; Jean-Daniel Tissot
Journal:  Transfus Med Hemother       Date:  2014-05-12       Impact factor: 3.747

3.  A Short Peptide Inhibitor as an Activity-Based Probe for Matriptase-2.

Authors:  Martin Mangold; Michael Gütschow; Marit Stirnberg
Journal:  Pharmaceuticals (Basel)       Date:  2018-05-21

4.  Transcriptomic Analysis of Streptococcus suis in Response to Ferrous Iron and Cobalt Toxicity.

Authors:  Mengdie Jia; Man Wei; Yunzeng Zhang; Chengkun Zheng
Journal:  Genes (Basel)       Date:  2020-09-02       Impact factor: 4.096

5.  3,1-Benzothiazines, 1,4-Benzodioxines and 1,4-Benzoxazines as Inhibitors of Matriptase-2: Outcome of a Focused Screening Approach.

Authors:  Polya G Roydeva; Anna-Madeleine Beckmann; Marit Stirnberg; Jožko Cesar; Danijel Kikelj; Janez Ilaš; Michael Gütschow
Journal:  Pharmaceuticals (Basel)       Date:  2016-01-13

6.  Intracellular autoactivation of TMPRSS11A, an airway epithelial transmembrane serine protease.

Authors:  Ce Zhang; Yikai Zhang; Shengnan Zhang; Zhiting Wang; Shijin Sun; Meng Liu; Yue Chen; Ningzheng Dong; Qingyu Wu
Journal:  J Biol Chem       Date:  2020-07-15       Impact factor: 5.157

7.  3-Amidinophenylalanine-derived matriptase inhibitors can modulate hepcidin production in vitro.

Authors:  Erzsébet Pászti-Gere; Gergely Szombath; Michael Gütschow; Torsten Steinmetzer; András Székács
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-10-28       Impact factor: 3.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.